1. Home
  2. BRID vs MAIA Comparison

BRID vs MAIA Comparison

Compare BRID & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgford Foods Corporation

BRID

Bridgford Foods Corporation

N/A

Current Price

$7.90

Market Cap

72.0M

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.28

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRID
MAIA
Founded
1932
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.0M
77.1M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
BRID
MAIA
Price
$7.90
$1.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7K
547.8K
Earning Date
06-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$174,257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.21
N/A
52 Week Low
$7.00
$0.87
52 Week High
$8.73
$3.19

Technical Indicators

Market Signals
Indicator
BRID
MAIA
Relative Strength Index (RSI) 54.00 47.43
Support Level $7.31 $1.24
Resistance Level $8.07 $1.46
Average True Range (ATR) 0.20 0.08
MACD 0.01 0.00
Stochastic Oscillator 64.74 33.19

Price Performance

Historical Comparison
BRID
MAIA

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: